YU74703A - Lipozomsko ciljanje inhibitora mreže metaloproteinaze - Google Patents

Lipozomsko ciljanje inhibitora mreže metaloproteinaze

Info

Publication number
YU74703A
YU74703A YU74703A YUP74703A YU74703A YU 74703 A YU74703 A YU 74703A YU 74703 A YU74703 A YU 74703A YU P74703 A YUP74703 A YU P74703A YU 74703 A YU74703 A YU 74703A
Authority
YU
Yugoslavia
Prior art keywords
matrix metalloproteinase
metalloproteinase inhibitors
liposomes
tumor cells
cells
Prior art date
Application number
YU74703A
Other languages
English (en)
Inventor
Medina Oula Penate
Erkki Koivunen
Paavo Kinnunen
Original Assignee
Licentia Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licentia Ltd. filed Critical Licentia Ltd.
Publication of YU74703A publication Critical patent/YU74703A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Sadašnji pronalazak se odnosi na terapiju ciljanja kancera, i tiče se specifično upotrebe inhibitora male mreže metaloproteinaze u poboljšanju ciljanja lipozoma na ćelije kancera, i u pojačavanju njihovog primanja od strane takvih ćelija. Pronalazak tako obezbeđuje postupak lečenja kancera, kao i postupak za poboljšano ciljanje lipozoma na ćelije tumora, postupak za pojačavanje primanja lipozoma od strane ćelija tumora, i postupak za selektiranu lipozomsku isporuku hemoterapeutskih sredstava u ćelije tumora.[The present invention relates to targeted cancer therapy, and concerns specifically the use of small matrix metalloproteinase inhibitors in improving targeting of liposomes to cancer cells, and in enhancing the uptake thereof to such cells. The invention thus provides a method for treating cancer, as well as a method for improving targeting of liposomes to tumor cells, a method for enhancing the uptake of liposomes by tumor cells, and a method for selected liposomal delivery of chemotherapeutic agents into tumor cells.
YU74703A 2001-03-26 2002-03-26 Lipozomsko ciljanje inhibitora mreže metaloproteinaze YU74703A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20010620A FI113840B (fi) 2001-03-26 2001-03-26 Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa

Publications (1)

Publication Number Publication Date
YU74703A true YU74703A (sh) 2006-05-25

Family

ID=8560842

Family Applications (1)

Application Number Title Priority Date Filing Date
YU74703A YU74703A (sh) 2001-03-26 2002-03-26 Lipozomsko ciljanje inhibitora mreže metaloproteinaze

Country Status (23)

Country Link
US (2) US20040213833A1 (sh)
EP (1) EP1372694B1 (sh)
JP (1) JP2004529127A (sh)
KR (1) KR20040000414A (sh)
CN (1) CN1250279C (sh)
AT (1) ATE331526T1 (sh)
BR (1) BR0208681A (sh)
CA (1) CA2441227A1 (sh)
CZ (1) CZ20032805A3 (sh)
DE (1) DE60212814T2 (sh)
DK (1) DK1372694T3 (sh)
EE (1) EE200300467A (sh)
ES (1) ES2266458T3 (sh)
FI (1) FI113840B (sh)
HU (1) HUP0303649A3 (sh)
IL (1) IL158114A0 (sh)
NO (1) NO20034280L (sh)
NZ (1) NZ528043A (sh)
PL (1) PL365248A1 (sh)
RU (1) RU2003131332A (sh)
SK (1) SK12982003A3 (sh)
WO (1) WO2002076491A1 (sh)
YU (1) YU74703A (sh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
IL152609A0 (en) * 2002-11-03 2003-06-24 Hapto Biotech Inc Liposomal compositions comprising haptotactic peptides and uses thereof
CN1314704C (zh) * 2002-11-20 2007-05-09 中国人民解放军军事医学科学院放射与辐射医学研究所 基质金属蛋白酶2的小肽抑制剂
EP1594550A4 (en) * 2003-01-24 2007-07-11 Barnes Jewish Hospital CHELATBILDNER WITH LIPOPHILES
FI115035B (fi) * 2003-05-02 2005-02-28 Ctt Cancer Targeting Tech Oy In vivo -kuvantaminen käyttäen peptidijohdannaisia
FI20031528A0 (fi) * 2003-10-17 2003-10-17 Ctt Cancer Targeting Tech Oy Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi
FI20040572A0 (fi) * 2004-04-23 2004-04-23 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasin aktiviteetin inhibiittorit
FI20040682A0 (fi) * 2004-05-14 2004-05-14 Ctt Cancer Targeting Tech Oy Tuumorien ja mestastaasien kuvantaminen käyttäen gelatinaasiin targetoituvaa peptidiä
FR2870741B1 (fr) 2004-05-25 2008-03-14 Coletica Sa Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant.
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
AU2007269609B2 (en) * 2006-07-06 2012-09-13 Board Of Regents Of The University Of Nebraska Polychromatic, diversely-sized particles for angiography
CN102114000B (zh) * 2009-12-31 2013-08-21 复旦大学 一种载药的共输送脂质纳米递药系统
US8871189B2 (en) 2011-11-30 2014-10-28 Mallinckrodt Llc MMP-targeted therapeutic and/or diagnostic nanocarriers
US11339209B2 (en) 2016-11-14 2022-05-24 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158760A (en) * 1990-05-30 1992-10-27 Board Of Regents, The University Of Texas System 99m TC labeled liposomes
WO1998016240A1 (en) * 1996-10-15 1998-04-23 The Liposome Company, Inc. Peptide-lipid conjugates, liposomes and liposomal drug delivery
FI980604A0 (fi) * 1998-03-18 1998-03-18 Univ Helsinki Licensing Nya matrismetalloproteinasinhibitorer och -regulatorer

Also Published As

Publication number Publication date
FI20010620A0 (fi) 2001-03-26
JP2004529127A (ja) 2004-09-24
FI20010620A (fi) 2002-09-27
NZ528043A (en) 2005-08-26
EP1372694A1 (en) 2004-01-02
HUP0303649A3 (en) 2005-12-28
NO20034280D0 (no) 2003-09-25
RU2003131332A (ru) 2005-04-10
NO20034280L (no) 2003-11-25
DE60212814D1 (de) 2006-08-10
CN1250279C (zh) 2006-04-12
CN1531439A (zh) 2004-09-22
DK1372694T3 (da) 2006-10-30
IL158114A0 (en) 2004-03-28
HUP0303649A2 (hu) 2004-01-28
SK12982003A3 (sk) 2004-08-03
BR0208681A (pt) 2004-03-30
ES2266458T3 (es) 2007-03-01
EP1372694B1 (en) 2006-06-28
CZ20032805A3 (cs) 2004-06-16
EE200300467A (et) 2003-12-15
ATE331526T1 (de) 2006-07-15
US20050271588A1 (en) 2005-12-08
WO2002076491A1 (en) 2002-10-03
FI113840B (fi) 2004-06-30
PL365248A1 (en) 2004-12-27
KR20040000414A (ko) 2004-01-03
DE60212814T2 (de) 2007-02-08
CA2441227A1 (en) 2002-10-03
US20040213833A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
IL158114A0 (en) Liposome targeting of matrix metalloproteinase inhibitors
WO2003002595A3 (en) Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
NO20014058L (no) TRPM-2-antisense-terapi
WO2006052900A3 (en) Targeted innate immunity
MXPA02011913A (es) Triazolopirimidinas sustituidas como agentes anticancer.
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
EA200700686A1 (ru) Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии
MXPA03004095A (es) Complejos de sn-38 con lipidos y sus metodos de uso.
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
CY1110329T1 (el) Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743
BR0213424A (pt) Uso aperfeiçoado de composto antitumoral na terapia contra câncer
AU2001272017A1 (en) Targeted combination immunotherapy of cancer and infectious diseases
AU5574001A (en) Method for treatment of tumors using photodynamic therapy
WO2003106640A3 (en) CELL TARGETING METHODS AND COMPOSITIONS
WO2005053725A3 (en) Cancer treatment
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
SE0100684D0 (sv) New subject-matter
EP1303520A4 (en) THERAPEUTIC COMPOUNDS AND METHODS
AU7548901A (en) Liposomal encapsulation of chelated actinium-225 and uses thereof
WO2004052282A3 (en) Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
GB2431656A (en) HAI-1 and HAI-2 in cancer therapy
ATE391777T1 (de) Verwendung von prohibitin-rns in krebsbehandlung
WO2002078718A3 (en) Compositions, methods and apparatuses for singlet oxygen delivery
WO2006020557A3 (en) Methods of using or identifying agents that inhibit cancer growth